1 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin70, 7-30, doi:10.3322/caac.21590 (2020).
2 Bunn, P. A., Jr. & Dimou, A. Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. J Clin Oncol36, 2571-2574, doi:10.1200/jco.2018.79.2457 (2018).
3 Hellman, S. & Weichselbaum, R. R. Oligometastases. J Clin Oncol13, 8-10, doi:10.1200/jco.1995.13.1.8 (1995).
4 Dingemans, A. C. et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol14, 2109-2119, doi:10.1016/j.jtho.2019.07.025 (2019).
5 Gomez, D. R. et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. The Lancet. Oncology17, 1672-1682, doi:10.1016/s1470-2045(16)30532-0 (2016).
6 Iyengar, P. et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol4, e173501, doi:10.1001/jamaoncol.2017.3501 (2018).
7 Palma, D. A. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England)393, 2051-2058, doi:10.1016/s0140-6736(18)32487-5 (2019).
8 Ashworth, A., Rodrigues, G., Boldt, G. & Palma, D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer82, 197-203, doi:10.1016/j.lungcan.2013.07.026 (2013).
9 Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol11, 39-51, doi:10.1016/j.jtho.2015.09.009 (2016).
10 Decoster, L. et al. Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. Lung195, 619-626, doi:10.1007/s00408-017-0025-2 (2017).
11 Wang, S. et al. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol30, 1447-1455, doi:10.1200/jco.2011.39.5269 (2012).
12 Chang, J. Y. et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet. Oncology16, 630-637, doi:10.1016/s1470-2045(15)70168-3 (2015).
13 Li, H. et al. Promising Clinical Outcome With Long Term Follow-Up After Body Gamma Knife Stereotactic Radiosurgery for Patients With Early Stage Non-small Cell Lung Cancer. Front Oncol8, 618, doi:10.3389/fonc.2018.00618 (2018).
14 Xia, T. et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys66, 117-125, doi:10.1016/j.ijrobp.2006.04.013 (2006).
15 De Rose, F. et al. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. Clinical oncology (Royal College of Radiologists (Great Britain))28, 13-20, doi:10.1016/j.clon.2015.08.011 (2016).
16 Milano, M. T., Katz, A. W., Zhang, H. & Okunieff, P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys83, 878-886, doi:10.1016/j.ijrobp.2011.08.036 (2012).
17 Goodman, B. D., Mannina, E. M., Althouse, S. K., Maluccio, M. A. & Cárdenes, H. R. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Practical radiation oncology6, 86-95, doi:10.1016/j.prro.2015.10.011 (2016).
18 Correa, R. J., Salama, J. K., Milano, M. T. & Palma, D. A. Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management. Cancer journal (Sudbury, Mass.)22, 247-256, doi:10.1097/ppo.0000000000000202 (2016).
19 Heitmann, J. & Guckenberger, M. Perspectives on oligometastasis: challenges and opportunities. J Thorac Dis10, 113-117, doi:10.21037/jtd.2017.12.77 (2018).
20 Xu, Q. et al. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. J Thorac Oncol13, 1383-1392, doi:10.1016/j.jtho.2018.05.019 (2018).
21 DeGregorio, M., Soe, L. & Wolf, M. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis6, 571-573, doi:10.3978/j.issn.2072-1439.2014.05.15 (2014).
22 Giaccone, G. et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer51, 2321-2329, doi:10.1016/j.ejca.2015.07.035 (2015).
23 Herrera, F. G., Bourhis, J. & Coukos, G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin67, 65-85, doi:10.3322/caac.21358 (2017).